Previous 10 | Next 10 |
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30 th NEXLIZET™...
Esperion Therapeutics (NASDAQ: ESPR ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, after market close. The consensus EPS Estimate is -$3.24 (-205.5% Y/Y) and the consensus Revenue Estimate is $0.39M vs. $145.4M in 1Q19. Over the last 2 years, ESPR has beaten EPS...
ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and conference call at...
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Exp...
The Food and Drug Administration (FDA) made numerous drug approval decisions in the first quarter. These binary events can cause stock prices to skyrocket or plummet depending on the outcome. Here we explore four companies that successfully attained FDA approval. It marked the first drug ever...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020, at ...
As expected, the European Commission has approved Esperion Therapeutics' (NASDAQ: ESPR ) Nustendi (bempedoic acid and ezetimibe) for adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia as an adjunct to diet: More news on: Esperion Thera...
– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe – – NUSTENDI Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other Lipid-Lowering Therapies, or Considered Statin Intolerant ...
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other Lipid-Low...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...